Tirzepatide and Kidney Protection in Obesity

In their recent JASN article, Heerspink et al. present a compelling post hoc analysis of the Tirzepatide Once Weekly for the Treatment of Obesity Trials-1 (SURMOUNT-1) and SURMOUNT-2 trials, demonstrating that tirzepatide reduces albuminuria in individuals with obesity or overweight—with or without type 2 diabetes—without adverse eGFR changes.1 This work underscores tirzepatide's potential for cardiorenal protection in high-risk populations. Although this study robustly addresses key outcomes, several considerations could further enhance its clinical relevance. First, racial and ethnic heterogeneity in obesity-related kidney disease warrants attention. African American individuals exhibit higher risks of obesity-related CKD and albuminuria progression, partly due to APOL1 variants and socioeconomic disparities.2 In SURMOUNT-1/-2, >70% of participants were White. Subgroup analyses by race and ethnicity could clarify whether tirzepatide's albuminuria-lowering efficacy is uniform across populations, informing equitable implementation in diverse clinical settings. Second, tubular health markers (e.g., kidney injury molecule-1, neutrophil gelatinase–associated lipocalin) may complement urine albumin-to-creatinine ratio (UACR) assessments. Obesity directly promotes tubular injury through lipotoxicity and inflammation,3 yet this study focused solely on glomerular parameters (UACR/eGFR). Including tubular biomarkers would elucidate whether tirzepatide mitigates both glomerular and tubular damage—critical for understanding its nephroprotective scope, particularly in early CKD. Third, comparative efficacy against glucagon-like peptide-1 receptor agonist (GLP-1 RAs) remains unexplored. Semaglutide reduced CKD progression in the Semaglutide Effects on Kidney Outcomes trial,4 but head-to-head data with tirzepatide are lacking. Given tirzepatide's dual glucose-dependent insulinotropic polypeptide/GLP-1 agonism, analyzing whether UACR reductions exceed those with selective GLP-1 RAs (e.g., semaglutide) could guide therapy selection for high-risk patients. In conclusion, Heerspink et al. provide pivotal evidence for tirzepatide's kidney benefits. Evaluating racial disparities, tubular injury biomarkers, and comparative efficacy against GLP-1 RAs would strengthen personalized strategies for obesity-related CKD. Future trials—particularly in advanced CKD cohorts—could validate these mechanistic and clinical extensions.